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small numbers with limited follow-up. Only one report
was identified in which PAS (n = 8) was compared with
OS (n = 9) to document the relative efficacy and long-
term follow-up; once again, the small sample size
negated the performance of statistical tests that would
have been able to detect anything but a very strong
association.23 Therefore, at present there is not enough
evidence to conclusively determine the best form of
therapy. The current study was undertaken to determine
the role of PAS and OS in the management of patients
with chronic mesenteric ischemia.
PATIENTS AND METHODS
Data retrieval. Patients treated with angioplasty with
or without stenting for symptoms of chronic mesenteric
ischemia were prospectively entered into an endovascular
database. Patient demographics, details of treatment, and
outcome were supplemented with retrospective chart
reviews. All (n = 28) pre- and post-PAS angiograms were
reviewed to establish the severity of stenosis and the num-
ber of vessels involved. Long-term follow-up was assessed
by means of the patients’ symptoms and duplex scan eval-
uation of mesenteric flow. When necessary, patients were
contacted by telephone and asked to return for duplex
scan flow assessment. Repeat angiograms were obtained
for new symptoms or evidence of recurrent stenosis on fol-
low-up duplex scan evaluation. Information regarding OS
patients was available from a series that previously was
reported from the same institution in the Journal of
Atherosclerotic occlusive disease of the mesenteric
circulation is an uncommon disorder that may culminate
in fatal intestinal gangrene, if not detected and treated.
Open surgical (OS) revascularization has been reported
to have excellent symptomatic cure and durability.1-5
Unfortunately, surgical revascularization is associated
with perioperative complications in the range of 19% to
54%1,4,5-8 with mortality rates ranging from 0% to
17%.1-18 Recent interest in minimally invasive endovas-
cular therapy for atherosclerotic short-segment occlu-
sive disease has extended to the management of chronic
mesenteric ischemia.19-27 Proponents of percutaneous
angioplasty and stenting (PAS) for symptoms of chronic
mesenteric ischemia have noted lower complications
rates in the range of 0% to 25%19-27 and a low peripro-
cedural mortality rate of 0% to 13%.19-27 However, most
series of PAS for chronic mesenteric ischemia include
63
From the Department of Vascular Surgerya and the Department of Vascular
Medicine,b The Cleveland Clinic Foundation.
Competition of interest: nil.
Presented at the Joint Meeting of the Society for Vascular Surgery and the
American Association for Vascular Surgery, Toronto, Ontario, Canada,
Jun 11-12, 2000.
Reprint requests: Kenneth Ouriel, MD, The Department of Vascular
Surgery, Desk S-61, The Cleveland Clinic Foundation, Cleveland,
OH 44195.
Copyright © 2001 by The Society for Vascular Surgery and The American
Association for Vascular Surgery.
0741-5214/2001/$35.00 + 0 24/6/111808
doi:10.1067/mva.2001.111808
Chronic mesenteric ischemia: Open surgery versus
percutaneous angioplasty and stenting
Karthikeshwar Kasirajan, MD,a Patrick J. O’Hara, MD,a Bruce H. Gray, DO,b Norman R. Hertzer,
MD,a Daniel G. Clair, MD,a Roy K. Greenberg, MD,a Leonard P. Krajewski, MD,a Edwin G. Beven,
MD,a and Kenneth Ouriel, MD,a Cleveland, Ohio
Objective: The aim of the study was to evaluate the safety and efficacy of percutaneous angioplasty and stenting (PAS)
in comparison with traditional open surgical (OS) revascularization for the treatment of chronic mesenteric ischemia.
Methods: Over a 3.5-year period, 28 patients (32 vessels) underwent PAS (balloon angioplasty alone, 5 [18%] of 28;
angioplasty and stenting, 23 [82%] of 28) for symptoms of chronic mesenteric ischemia. These patients were compared
with a previously published series of 85 patients (130 vessels) treated with OS (bypass grafting, 60 [71%] of 85;
transaortic endarterectomy, 19 [22%] of 85; or patch angioplasty, 6 [7%] of 85).
Results: The PAS and OS groups were similar with respect to baseline comorbidities, duration of symptoms (median:
6.7 vs 10.5 months, P = .52), and the number of vessels involved, but the patients differed in their age at presentation
(median: 72 vs 65 years, P = .005). Fewer vessels were revascularized per patient in the PAS group (1.1 ± 0.4) com-
pared with the OS group (1.5 ± 0.6, P = .001). Overall, 85.7% (24/28) had one vessel and 14.3% (4/28) had two ves-
sels revascularized in the PAS group versus 48.2% (41/85) with one-vessel and 47.1% (40/85) with two-vessel
revascularization in the OS group. No difference was noted in the early in-hospital complications (median: 17.9% [PAS]
vs 32.9% [OS], P = .12) or mortality rate (10.7% [PAS] vs 8.2% [OS], P = .71). A reduced length of hospital stay in
the PAS patients did not attain statistical significance (median: 5 days [PAS] vs 13 days [OS], P = .08). Although the
3-year cumulative recurrent stenosis (P = .62) and mortality rate (P = .99) did not differ, the PAS treatment group had
a higher incidence of recurrent symptoms (P = .001).
Conclusion: Although the results of PAS and OS were similar with respect to morbidity, death, and recurrent stenosis,
PAS was associated with a significantly higher incidence of recurrent symptoms. These findings suggest that OS should
be preferentially offered to patients deemed fit for open revascularization. (J Vasc Surg 2001;33:63-71.)
Vascular Surgery.5 If necessary, changes were made to this
database in a retrospective fashion in an effort to produce
comparable reporting standards for both groups.
Patient selection. Only patients with a classic history
for chronic mesenteric ischemia (postprandial abdominal
pain, bloating, weight loss, “food fear,” nausea, vomiting,
diarrhea, and/or constipation) were included in the study.
Patients presenting with acute mesenteric ischemia or
nonatherosclerotic mesenteric occlusive disease were
excluded. Among patients with PAS, 23 of 28 were seen by
a gastroenterologist for complaints of chronic abdominal
pain; chronic mesenteric ischemia was diagnosed only after
exhaustive clinical and laboratory investigations were per-
formed to exclude nonvascular causes for the abdominal
pain and weight loss. The vascular surgery and vascular
medicine team evaluated the five other patients. The preop-
erative risk factors were those as defined by the Society for
Vascular Surgery and the American Association for Vascular
Surgery, a chapter of the International Society for
Cardiovascular Surgery. These were grouped together for
the purpose of comparison. Events that resulted in a pro-
longed hospital stay by more than 48 hours were defined as
complications. The mortality rate was not included in the
evaluation of complications, but was reported separately.
Diagnosis and treatment methods. The noninvasive
laboratory criterion for an occluded mesenteric vessel was
a clearly visualized vessel with no color flow or Doppler
scan signal. Celiac artery stenosis of 70% to 99% was diag-
nosed if the peak systolic velocity was more than 250 cm/s
with poststenotic turbulence. Superior mesenteric artery
(SMA) or inferior mesenteric artery (IMA) stenosis of 70%
to 99% was diagnosed when the peak systolic velocity was
more than 275 cm/s with poststenotic turbulence.28 This
was confirmed with a diagnostic angiogram before further
treatment. Angiographic determination of the stenosis was
done by comparing the area of maximum narrowing with
the vessel beyond the site of stenosis. Technical success in
the PAS group was defined as a residual stenosis < 30% or
a residual pressure gradient of less than 10 mm Hg.
Recurrent stenosis or occlusion was determined with
duplex scan or angiographic assessment.
Statistical methods. Categoric variables in the PAS
and OS groups were compared at baseline and postproce-
dure with either a χ2 or Fisher exact test, and the contin-
uous variables were compared with either a 2-sided t test
or the Wilcoxon rank sum test, as appropriate. Median val-
ues were used when data were nongaussian in distribution.
Kaplan-Meier analysis was used to estimate survival and
survival to first known recurrence of stenosis or symptoms.
A 2-tailed P value of .05 was considered significant for
each hypothesis. SAS statistical software (SAS Institute,
Inc, Cary, NC) was used for all analyses.29
RESULTS
Patient demographics. Twenty-eight patients (32 ves-
sels) were treated in the PAS group from February 1995 to
June 1998, and 85 patients (130 vessels) were treated in the
OS group from September 1977 to June 1997. There was
a higher prevalence of smokers in the OS group (88% vs
61%, P = .002), and a higher proportion of patients in the
PAS group had coronary artery disease (68% vs 33%, P =
.001). Otherwise, there were no differences between the
treatment groups (Table I). The preprocedural weight loss
(pounds) did not differ between the groups, with a median
of 25 lb (range, 15-60 lb) for the PAS group and a median
of 30 lb (range, 3-100 lb) for the OS group (P = .94,
Wilcoxon rank sum test). The duration of symptoms before
presentation to the physician was also indistinguishable
(PAS group: 6.7 months [range, 0-36 months]; OS group:
10.5 months [range, 0-64 months]; P = .52, Wilcoxon rank
sum test).
Vessels involved. The celiac artery, the SMA, and the
IMA were evaluated for the severity of stenosis on the
basis of the lateral abdominal aortogram. The PAS patients
had fewer occluded vessels than the OS patients (P = .001,
Wilcoxon rank sum test). However, the total number of
involved stenotic or occluded vessels per patient was simi-
lar between the groups, with a median of three vessels
(range, 1-3) in each group (2.5 ± 0.6 [PAS]; 2.6 ± 0.5
[OS]; P = .71) (Table II).
Treatment modalities. In the PAS group, angioplasty
combined with stenting was performed in 23 (82%) of 28
patients and angioplasty alone in 5 (18%) of 28. In this
group, the brachial approach was used in 17 (61%) patients
and the femoral approach in 11 (39%). Two of the brachial
approaches were conversions after initial attempts to can-
nulate the mesenteric artery from a femoral approach.
Balloon-expandable stents were used in 23 vessels, and self-
expanding stents in three vessels; the remaining six vessels
underwent angioplasty only. Occlusions were more likely
to be treated in the OS group, whereas most vessels were
treated for stenosis in the PAS group. Recanalization was
performed in only one (4%) of the 25 occluded vessels in
the PAS group, compared with the treatment of 62 (51%)
of the 122 occluded vessels in the OS group. The proce-
dures performed in the OS patients include bypass grafting
in 60 (71%) of 85 (retrograde bypass grafting, 40%; ante-
grade bypass grafting, 28%; reimplant and thrombectomy,
3%), eversion endarterectomy in 19 (22%) of 85, and patch
angioplasty in 6 (7%) of 85.
Treatment outcome. Significantly more vessels were
revascularized in the OS group compared with the PAS
group (P = .001, Wilcoxon rank sum test). In the PAS
group, 24 (85.7%) patients had only one vessel treated,
and four (14.3%) patients had two vessels treated. In com-
parison, 41 (48.2%) OS patients had one vessel revascular-
ized, 40 (47.1%) had two vessels, and three (4%) had three
vessels (insufficient data, 1 patient). Overall, the PAS
group had 1.1 ± 0.4 (range, 1-2) vessels treated per
patient compared with 1.5 ± 0.6 (range, 1-3) vessels per
patient in the OS group (P = .001; Table II).
There was a trend toward reduced length of hospital
stay in patients who underwent PAS (median, 5 days)
compared with the OS group (median, 13 days), but this
was not statistically significant (P = .08). However, there
was a greater variability in the PAS group (quartiles 0.5-43
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vs 9-20 for the OS group). Similarly, there was no differ-
ence in the overall incidence of perioperative complica-
tions (17.9% [PAS] vs 32.9% [OS], P = .12; Table III).
Bowel gangrene occurred in two (7%) of 28 patients in the
PAS group and in two (2%) of 85 in the OS group (P =
.24). Death in the PAS group was related to bowel gan-
grene and subsequent multisystem organ failure in two
patients, and one other patient died because of myocardial
infarction. Although there was no difference in the pro-
portion of patients with at least one perioperative compli-
cation between the groups, the proportion with at least
one systemic complication involving the cardiac, pul-
monary, gastrointestinal, or renal system was higher in the
OS group (19% [PAS] vs 40% [OS], P = .034). No access
site complications were noted in the PAS group.
Late follow-up. Follow-up data were collected for
deaths, recurrent stenosis/occlusion, or recurrent symp-
toms. There was no survival difference at 3 years between
the groups (81% [PAS] vs 71% [OS], P = .99; Fig 1).
Survival data were available for as long as 13 years in the OS
group (28%; 95% CI, 13%-43%) and to 5 years in the PAS
group. The mean follow-up time was 5 years for the OS
group and 2 years for the PAS treatment group. Among
patients in the PAS group, the estimated Kaplan-Meier sur-
vival was 60% at 5 years (95% CI, 24%-96%), compared with
64% (95% CI, 53%-75%) in the OS group. Objective data
for patency estimates were available in 19 (68%) patients in
the PAS group (only 1 patient in the PAS group had a
repeat angiogram) and for 54 (64%) patients in the OS
group. At 3 years, occlusion and recurrent stenosis were
documented in 27% (95% CI, 0%-55%) of the PAS group
compared with 24% (95% CI, 14%-34%) of the OS group
(P = .62; Fig 2). Among the PAS treatment group, vessels
that underwent angioplasty only had two (33%) recurrent
stenoses, and the those that underwent angioplasty with
stenting had three (11.5%) recurrent stenoses/occlusions.
Patients were also questioned for evidence of recur-
rent symptoms. Among the PAS treatment group, 11
patients had recurrent symptoms. Four of the 11 patients
underwent no further evaluation. The seven remaining
patients underwent duplex scan or angiographic assess-
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ment. Only one of these seven patients had a recurrent
lesion that was identified and underwent angioplasty
again. The six other patients with no evidence of recurrent
stenosis were followed up clinically. None of these patients
had worsening of symptoms or acute mesenteric ischemia
during the follow-up interval. On the contrary, in the OS
group, recurrent symptoms coincided with objective evi-
dence of graft or arterial occlusion in nine (90%) of 10
patients. Overall, cumulative recurrent symptoms at 3
years were more common in the PAS treatment group
(34%, 95% CI 14%-54%) compared with the OS treatment
Table I. Comparing groups on risk factors
Endovascular OS P
Risk factor (n = 28) (n = 85) value*
Age (y) 68 ± 15 62 ± 11 .005 t
Female 21 (75%) 60 (71%) .65
Smoking 17 (61%) 75 (88%) .002
Hypertension 22 (79%) 50 (59%) .052
Coronary artery disease 19 (68%) 28 (33%) .001
COPD 4 (14%) 27 (32%) .06
Renal disease 5 (18%) 14 (16%) .99 F
Hyperlipidemia 1 (4%) 10 (12%) .29 F
Diabetes mellitus 3 (11%) 5 (6%) .41 F
*χ2 Test unless noted.
COPD, Chronic obstructive pulmonary disease; F, Fischer exact test; OS,
open surgery; t, 2-sided t test.
Table II. Vessels involved in stenosis and/or occlusion
and treated vessels
Surgery Endovascular
Vessels (n = 85) (n = 28)
Involved
SMA only 4 (5%) 1 (4%)
SMA, CA 22 (26%) 7 (25%)
SMA, IMA 10 (12%) 5 (18%)
SMA, CA, IMA 49 (58%) 15 (54%)
Total 215 70
Occluded
None 11 (13%) 6 (22%)
SMA 11 (33%) 1 (4%)
CA 6 (7%) 4 (15%)
IMA 16 (19) 14 (50)
SMA, CA 15 (18%) —
CA, IMA 5 (6%) 3 (11%)
SMA, IMA 11 (13%) —
SMA, CA, IMA 9 (11%) —
Total 122 25
Treated
SMA 1 (1%) 23 (82%)
CA 39 (46%) 1 (4%)
IMA 1 (1%) —
SMA, CA 29 (34%) 3 (11%)
SMA, IMA 11 (13%) 1 (4%)
SMA, CA, IMA 3 (4%) —
Total 130 32
CA, Celiac artery; IMA, inferior mesenteric artery; SMA, superior mesen-
teric artery.
Table III. Postoperative complications and death
Complications PAS (n = 28) OS (n = 85) P value*
Cardiac 1 (4%) 12 (14%) .18
Pulmonary 1 (4%) 14 (16%) .11
Gastrointestinal 4 (14%) 25 (29%) .10
Bowel gangrene 2 (7%) 2 (2%) .24
Ileus 0 (0%) 25 (29%) < .001
DIC 0 (0%) 1 (1%) > .99
Renal 0 (0%) 7 (8%) .19
Others 0 (0%) 3 (4%) .57
Any of the above 5 (18%) 28 (33%) .12
Death 3 (11%) 7 (8%) .71
*Fischer exact or χ2 test, as appropriate (P < .05 significant).
DIC, Disseminated intravascular coagulation; OS, open surgery; PAS, per-
cutaneous angioplasty and stenting.
group (13%, 95% CI 6%-21%, P = .001; Fig 3). Most of
the symptomatic recurrences in the PAS treatment group
occurred within the first year; there was 28% recurrence at
1 year and 34% at 3 years. Subgroup analysis of 41 OS
patients and 24 PAS patients with only a single vessel
treated revealed no difference in patency (P = .37) or
recurrent mesenteric symptoms (P = .31) at 3 years.
DISCUSSION 
The goals of revascularization in patients with symp-
tomatic chronic mesenteric ischemia are to relieve symp-
toms, improve the nutritional status, and prevent intesti-
nal infarction. Prophylactic mesenteric revascularization
rarely is performed in the asymptomatic patient undergo-
ing an aortic procedure for other indications. However,
the natural history of untreated chronic mesenteric
ischemia may justify revascularization in some asymp-
tomatic patients if the operative risks are acceptable.30 In
the only available natural history study, 86% of patients
with significant three-vessel arterial disease had mesenteric
ischemia, had vague abdominal symptoms, or died.30 The
first clinical presentation may be acute mesenteric ischemia
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Fig 1. Cumulative overall survival comparing OS treatment group with endovascular treatment group (P = .99; SE > 10 for PAS group
beyond 4 years).
Fig 2. Cumulative patency comparing OS treatment group with endovascular treatment group (P = .62; SE > 10 for PAS group beyond
2 years).
in about 15% to 50% of the patients, with a mortality rate
of 15% to 70%.31,32 Until recently, OS revascularization
was the only available treatment for patients with chronic
mesenteric ischemia. Complex anatomy, technical chal-
lenges encountered for OS exposure of the paravisceral
aorta, and the physiologic changes often associated with
surgical treatment in these patients have prompted inter-
est in minimally invasive endovascular options.
The small sample size of PAS parallels the OS experi-
ence in the management of patients with chronic mesen-
teric ischemia. Because of the numerous causes for chronic
abdominal pain, diagnosis is often difficult, and the treat-
ment remains challenging whether performed percuta-
neously or operatively. Several years were required to
collect a relatively small number of patients with chronic
mesenteric ischemia in most reports; thus, no prospective,
randomized trial of PAS versus OS is currently available
regarding management.
In 1995, Rose et al23 published the only available ret-
rospective comparison between the two treatment modal-
ities. The initial technical success for PAS was a dismal
30% (with a residual stenosis < 30% as the end point)
compared with 100% for the OS group. However, if a
residual stenosis rate of < 50% was taken to be the end
point, their primary technical success rate increased to
88%. The reported mortality rate (13% [PAS], 11% [OS])
and the nonfatal major complication rate (25% [PAS],
33% [OS]) were similar in both groups. More vessels were
revascularized in the OS group compared with the PAS
group. In the OS group, seven (78%) of the nine reported
patients had two vessels revascularized compared with
only one (13%) of the eight patients in the PAS group.
Long-term pain relief was only 67% at 9.2 months in the
PAS group compared with 88% at 34.5 months in the OS
group. These authors concluded that long-term symp-
tomatic relief was superior in the OS group compared
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with the PAS group, possibly reflecting the number of
vessels revascularized.
A summary of the data published over the last decade
for the management of chronic mesenteric ischemia with
either OS or PAS is given in Tables IV and V. Case reports
and series with fewer than five patients were not included,
because there may have been a bias toward publication of
cases with favorable outcomes. Because OS revasculariza-
tion has been traditionally used and is considered to be the
criterion standard, the number of patients in OS studies
(490 [OS]; 122 [PAS]) is larger and is associated with a
longer period of follow-up (66 ± 27 months [OS] vs 27 ±
8 months [PAS]). The methods used for assessment of
technical success were variable for the PAS group, and
objective evidence for patency either was not uniformly
available or was subject to variability in reporting standards.
Pain relief was considered the most important indica-
tor of long-term success. Significantly more vessels were
revascularized in the OS treatment group compared with
the PAS treatment group: a mean of 49 ± 28 patients had
86 ± 53 vessels revascularized in the OS group versus 17
± 7 patients with 23 ± 12 vessels revascularized in the PAS
group (Tables IV and V). Overall, 1.8 vessels per patient
were revascularized in the OS studies compared with 1.3
vessels per patient in the PAS reports. This may have
resulted from preferentially treating stenosis rather than
occlusions in the PAS cohorts. Endovascular recanaliza-
tion of complete arterial occlusions is usually more chal-
lenging, resulting in a higher incidence of complications
and often being associated with lower long-term patency.
In our current study, occlusions were more likely to be
treated with open bypass grafting compared with PAS
(PAS, 4%; OS, 51%). There was also a higher incidence of
preprocedure arterial occlusions in the OS group, proba-
bly reflecting a selection bias toward OS therapy for this
patient population.
Fig 3. Cumulative freedom from recurrent symptoms comparing OS treatment group with endovascular treatment group (P = .001; SE
< 10 for all values).
In the summary of published trials, immediate pain
relief was more likely in the OS treatment group (Tables
IV and V) compared with the PAS patients (100% [OS] vs
79% ± 9% [PAS]). However, immediate relief of pain could
conceivably be a result of the placebo effect of the proce-
dure or of pain medications used in the postoperative
period, both of which probably play a greater role in OS
patients. During a mean follow-up of 66 ± 27 months,
sustained freedom from recurrent symptoms was noted in
85% ± 12% of the OS patients compared with 72% ± 10%
during a shorter period of follow-up (27 ± 8 months) in
the PAS patients. In aggregate, complication rates (29% ±
12% [OS] vs 18% ± 15% [PAS]) and mortality rates (7%
[OS] vs 4% [PAS]) were higher in the OS treatment group
than in the PAS case reports.
Definitive conclusions cannot be inferred from the pre-
vious literature because of variable reporting standards.
However, long-term pain relief has been universally reported
to be better in the OS series. The possible reasons for a sus-
tained freedom from recurrent symptoms are speculative.
The number of vessels revascularized has often been reported
to influence the long-term outcome.4,5 McAfee et al4 evalu-
ated the results of total revascularization in comparison with
incomplete revascularization. The 5-year survival rate for
patients with three-vessel involvement who underwent
three-vessel revascularization in this study was 73%, com-
pared with 57% for two-vessel revascularization and 0% for
one-vessel repair. Similarly, 5-year graft patency was better
for complete revascularization (90%, 54%, and 0%, respec-
tively).4 In our report, six patients in the PAS group had
recurrent symptoms with no objective evidence of restenosis
in the treated vessels. In comparison, nine of the 10 patients
with recurrent symptoms in the OS group had objective evi-
dence of restenosis in the treated vessels or graft conduits.
Thus, recurrent symptoms in the PAS group may be related
to progressive atherosclerotic narrowing of untreated vessels.
Unfortunately, the follow-up evaluation often did not
include objective evidence of patency in the untreated ves-
sels. Thus, the “progressive stenosis of untreated vessels”
hypothesis cannot be established. It is also possible that
recurrent abdominal symptoms in the PAS treatment group
may have been unrelated to progressive mesenteric arterial
occlusive disease, especially because they were not associated
with objective evidence of recurrent stenosis/occlusion.
Gentile et al33 reported their experience using isolated
bypass graft to the SMA as being comparable to the suc-
cess and durability of bypass grafts to multiple visceral ves-
sels. The authors reported 4-year primary patency and
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Table IV. Literature review of OS management of patients with mesenteric ischemia
Vessels Technical Immediate Follow-up Long-term Mortality
Author Year Pt no. revascularized success pain relief (mo) pain relief Complications rate Patency
Kieny15 1990 60 69 100% NA 102 NA NA 3.50% 75%
Cormier2 1991 32 90 100% NA 69 NA NA 9% 91%
Cunningham6 1991 74 194 100% 100% 71 86% 17.10% 12.20% NA
McAfee4 1992 58 119 100% NA 60 90% 41% 10% 90%
Calderon3 1992 20 36 100% 100% 36 100% 20% 0 100%
Christensen36 1994 90 109 100% NA 55 63% NA 13% NA
Gentile33 1994 26 29 100% 100% 48 89% NA 10% 89%
Johnston1 1995 21 43 100% NA 120 NA 19% 0 86%
Moawad11 1997 24 38 100% 100% 60 78% 45% 4% 78%
Mateo5 1999 85 130 100% 100% 36 87% 33% 8% 76%
Mean 49 86 100% 100% 66 85% 29% 7% 86%
SD 28 53 0 27 12% 12% 9%
NA, not applicable; OS, open surgical; Pt, patient.
Table V. Literature review of endovascular management of mesenteric artery stenosis
Vessels Technical Immediate Follow-up Long-term Mortality
Author Year Pt no. revascularized success pain relief (mo) pain relief Complications rate Patency
Matsumoto20 1995 19 20 79% 63% 25 52% 32% 0 NA
Hallisey19 1995 16 25 84% 81% 27.6 75% 6% 6% 75%
Allen37 1996 19 24 95% 79% 39 79% 5% 5% NA
Maspes21 1997 23 41 90% 77% 27 75% 9% 0 88%
Nyman35 1998 5 6 100% 80% 21 80% 40% 0 40%
Sheeran22 1999 12 13 92% 92% 15.7 75% NA 8% 74%
Present 2000 28 32 100% NA 36 66% 18% 11% 73%
Mean 17 23 91% 79% 27 72% 18% 4% 70%
SD 7 12 8% 9% 8 10% 15% 18%
NA, Not applicable; Pt, patient.
patient survival rates of 89% and 82%, respectively, and
symptomatic improvement was noted in all patients avail-
able for follow-up. Similarly, a subgroup analysis of our
patient population with single-vessel revascularization had
no difference in long-term outcome between OS and
endovascular treatment. This may be a reflection of the
importance of SMA revascularization. All single-vessel
recanalization in the PAS patients involved the SMA, fur-
ther supporting the study on isolated SMA bypass graft as
a durable option.33 However, multiple-vessel revascular-
izations were, overall, more durable (symptom-free inter-
val) than solitary SMA revascularization.
The retrospective observational nature of the current
study subjects it to numerous disadvantages. The treat-
ments were not randomly assigned but individually selected,
which resulted in some of the observed differences. This
may not be easily detected. The type of treatment (PAS vs
OS) was determined by a number of factors, including the
skills available to the physician evaluating the patient. In
addition, the sicker patients were more likely to have the less
invasive procedure (PAS), and multivessel involvement
more commonly had a surgical bypass graft. Moreover, the
nonstandardization of treatments within both groups makes
them an unsuitable comparison group. However, this is
often the fundamental problem when dealing with rare dis-
eases, such as chronic mesenteric ischemia.
Evidence-based medicine favors the use of the best
available information when deciding on the most appro-
priate treatment for a particular condition.38 However,
the evidence for the best treatment option for patients
with chronic mesenteric ischemia is limited and contro-
versial, especially since the introduction of endovascular
options. Despite the minimally invasive nature of percu-
taneous endovascular techniques, major complications are
not insignificant, and decreased flow to the mesenteric
vascular bed can still result in a grave outcome. Although
endovascular therapy may confer advantages with respect
to length of stay and speed of recovery, on the basis of
currently available data, the long-term durability (espe-
cially freedom from recurrent symptoms) of PAS is infe-
rior to OS revascularization.23 Fully cognizant of the
limitations of the current study, we recommend OS revas-
cularization as the procedure of choice in patients as an
acceptable risk for OS.
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Dr John Blebea (Hershey, Pa). I congratulate you on a nice
presentation and the extensive experience you have had with both
modalities. I rise to ask two questions. 
First, are these truly equivalent patient populations? In other
words, what selection factors predisposed patients to have one inter-
vention versus the other? Certainly in terms of coronary artery dis-
ease, it appears that the angioplasty group had more severe disease. 
Secondly, in looking at your symptom life table data, is it
recurrence of symptoms or persistence of symptoms in the angio-
plasty group? In examining those results, it appears that the
biggest decrease occurred during the earlier time period.
Especially with less vessels being revascularized, were those
patients undergoing angioplasty truly relieved of their symptoms
initially versus having recurrence later? 
Dr Karthikeshwar Kasirajan. Thank you for your comments.
To answer your first question on patient selection criteria, the
most important deciding factor was the underlying comorbid
conditions. As is shown in the table for risk factors, there was a
higher incidence of coronary artery disease in the angioplasty
group. The sicker patients, hence, preferentially underwent
angioplasty. The next deciding factor was the anatomical pattern
of mesenteric arterial stenosis. In general, endovascular proce-
dures are technically more challenging and riskier in patients with
occlusions. Hence, patients with multivessel involvement, partic-
ularly occlusions, were more commonly seen in the open surgical
treatment group. As always, in diseases with multiple treatment
options, the referral pattern also determined the therapeutic
modality. If the patient was referred to an intervention radiologist
or an endovascular surgeon, the patient had a greater probability
of having an angioplasty. On the contrary, referral to a surgeon
with no or minimal endovascular skills would result in a higher
probability of open surgical revascularization, provided the
patient was at an acceptable operative risk.
To answer your second question. As you had correctly
pointed out, a majority of the recurrent symptoms in the PTA
group occurred within the first year. In addition, in many patients
recurrent symptoms did not coincide with recurrent stenosis. The
initial pain relief may have been related to the postprocedure pain
medications and the placebo effect of the procedure. Follow-up
telephone communication only added to the confusion, as a
majority of the patients with “recurrent” symptoms said, “I don’t
think I ever got better.” Hence, “recurrent” symptoms may rep-
resent nothing more than a failed angioplasty or “persistent”
symptoms. 
About 5% of all emergency room admissions are for com-
plaints of abdominal pain. However, chronic mesenteric ischemia
is a rarely diagnosed entity. This also brings up the possibility that
the persistent or recurrent symptoms may be unrelated to the
mesenteric occlusive disease. 
Dr John J. Ricotta (Stony Brook, NY). That was a very nice
study. It sounds like you answered my first question, which was,
did you perform another angiogram of these patients when they
developed symptoms to know what the status of the angioplasty
was or the status of their arterial repair? 
Dr Kasirajan. If patients developed recurrent symptoms,
they initially had a duplex evaluation. Unfortunately, in the
angioplasty group, the recurrent symptoms often did not coin-
cide with recurrent stenosis. And if they did not have evidence
of recurrent stenosis on the duplex evaluation, they did not
undergo another angiogram. 
Dr Ricotta. Any information on stent versus PTA? You stented
some of these people and some you didn’t. 
Dr Kasirajan. On subgroup analysis, the numbers became very
small. The incidence of recurrent stenosis in the angioplasty-alone
group was 33%. And the angioplasty plus stenting group was 11%.
But the numbers were too small to perform meaningful statistical
analysis. 
Dr Takao Ohki (New York, NY). I completely agree with your
conclusion, number one, which is preferentially perform surgical
bypass. And I also understand your observation in regard to the
failure rate of the angioplasty. 
I have a strong objection, however, to your conclusion num-
ber two, which is when you perform angioplasty, revascularize as
many vessels as possible. I think there is a tremendous leap
between conclusion 1, observation 1, to conclusion 2 or recom-
mendation 2. Once you start recanalizing occluded vessels
endovascularly, then you’re going to start causing more harm
than good. So I think you should stop at conclusion 1 and keep
some reservation for angioplasty. If you start revascularizing every
occluded SMA and celiac as you recommend, you can cause a lot
of problems. What do you think about your conclusion 2? 
Dr Kasirajan. Your point is well taken. Percutaneous multivessel
angioplasty, especially in patients with occlusions, may increase the
risk of complications and procedure-related mortality. My last rec-
ommendation does not really apply to the angioplasty group but to
the open surgical treatment group. We feel multivessel revascular-
ization, when possible, should be attempted in all patients with
chronic mesenteric ischemia. Numerous other authors have simi-
larly demonstrated superior long-term patency, improved freedom
from recurrent symptoms, and a possible survival advantage for
multivessel revascularization, as opposed to solitary bypass. 
Dr Yaron Sternbach (Rochester, NY). Congratulations, I
think those are great data. 
Can you tell us, were you successful in all the procedures that
you attempted actually? And can you relate any of the recurrent
symptoms perhaps either to the length of the lesion you were
treating or to the length of the stent that you used? And to what
diameter did you dilate each of these vessels? 
Dr Kasirajan. Data were not collected on an intent-to-treat
basis. This was a retrospective study; only patients who were
recorded as having had a mesenteric angioplasty were available
from our computer registry. It is possible we may have had a large
subset of patients, where initial attempts to cross a stenosis or occlu-
sion failed. Unfortunately, these would not have been recorded as
a mesenteric angioplasty failure. This retrospective study does not
represent an intent-to-treat analysis, and we may be underreporting
our initial treatment failures for mesenteric angioplasty. 
To answer your second question, we did not routinely record
DISCUSSION
the length of occlusion/stenosis or the length of the stents that
we used. The majority of the stents used were balloon-expandable
Palmaz stents. On a rough estimate, the SMA was dilated to
approximately 6 mm and the celiac 8 mm. Particularly in the
mesenteric circulation, initial undersizing of the balloon may be
preferable to oversizing the balloon.
Dr John D. Edwards (Cincinnati, Ohio). The question is sim-
ple. The patients sounded sicker in the angioplasty group, but in
fact, the lesions were probably simpler and more straightforward
in the angioplasty group. So two died in surgery, and two died in
angioplasty. The question obviously that we would like to know
is, regarding the two that died of angioplasty or subsequent to it:
would they have had a better result with surgery? Now, I know
that’s impossible to answer, but we’d like your guess. 
And then the second question I have for you is, this may be
one of the areas—I think this is a very dangerous area. I think it’s
an interesting topic, but I think this is a very dangerous area. I think
these are dangerous lesions to try to take on from an endovascular
approach. And do you think that perfusion protection devices are
going to come into vogue for carotids and renals? Do you think
that maybe there’s a role in this, and do you think it might have
saved those two bowel infarcts in the angioplasty group?
Dr Kasirajan. There were two bowel infarcts noted in the
angioplasty group, one secondary to a dissection and the other
probably related to downstream embolization. Both patients
subsequently died. With improved techniques, better guidewire,
and distal protection devices, we may, to a certain extent, be able
to guard against distal embolization. However, the initial
attempt to pass a guidewire across the stenosis/occlusion may in
itself release embolic debris. Speaking futuristically, in a select
subset of patients, the use of lower profile systems with better
torque control may make mesenteric angioplasty a more attrac-
tive option, in comparison with the technically challenging open
surgical methods.
Whether open surgery would have served those two patients
better, as you have mentioned, is impossible for me to retro-pre-
dict; however, a dissection and a downstream embolization may
have been easily avoided with open surgical techniques. Thank you.
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